Schizophrenia Research
Volume 56, Issue 1 , Pages 75-85 , 1 July 2002

Serotonergic function and suicidal behavior in schizophrenia

  • Humberto Corrêa

      Affiliations

    • Centre Hospitalier, Secteur VIII, 68250 Rouffach, France
    • Department of Pharmacology, Instituto de Ciencias Biologicas, Universidade Federal de Minas Gerais, Avenida Antonia Carlos, 6627 Cep, 31280-901 Belo Horizonte Minas Gerais, Brazil
    • Corresponding Author InformationCorresponding author. Address: Department of Pharmacology, Instituto de Ciencias Biologicas, Universidade Federal de Minas Gerais, Avenida Antonia Carlos, 6627 Cep, 31280-901 Belo Horizonte Minas Gerais, Brazil. Tel.: +55-312-257-654
    • ,
  • Fabrice Duval

      Affiliations

    • Centre Hospitalier, Secteur VIII, 68250 Rouffach, France
    • ,
  • Marie-Claude Mokrani

      Affiliations

    • Institute for Research in Neuroscience and Psychiatry, 68250 Rouffach, France
    • ,
  • Paul Bailey

      Affiliations

    • Institute for Research in Neuroscience and Psychiatry, 68250 Rouffach, France
    • ,
  • Fabien Trémeau

      Affiliations

    • Centre Hospitalier, Secteur VIII, 68250 Rouffach, France
    • ,
  • Luc Staner

      Affiliations

    • Institute for Research in Neuroscience and Psychiatry, 68250 Rouffach, France
    • ,
  • Than-Son Diep

      Affiliations

    • Institute for Research in Neuroscience and Psychiatry, 68250 Rouffach, France
    • ,
  • Marc-Antoine Crocq

      Affiliations

    • Centre Hospitalier, Secteur VIII, 68250 Rouffach, France
    • ,
  • Jean-Paul Macher

      Affiliations

    • Centre Hospitalier, Secteur VIII, 68250 Rouffach, France

Received 21 August 2000 ,Revised 19 January 2001 ,Accepted 25 January 2001.

References 

  1. Abel KM, O'Keane V, Murray RM. Enhancement of the prolactin response to d-fenfluramine in drug-naive schizophrenic patients. Br. J. Psychiatry. 1996;168:57–61
  2. Abel KM, O'Keane V, Murray RM, Cleare A. Serotonergic function and negative and depressive symptomatology in Schizophrenia and major depression. Psychoneuroendocrinology. 1997;22:539–548
  3. Allebeck P. Schizophrenia: a life-shortening disease. Schizophrenia Bull. 1989;15:81–89
  4. Allebeck P, Varla A, Kristjansson E, Wistedt B. Risk factors for suicide among patients with schizophrenia. Acta Psychiatr. Scand. 1987;76:414–419
  5. Asberg M, Traskman L. Studies of CSF-5-HIAA in depression and suicidal behavior. Adv. Exp. Med. Biol. 1981;133:739–752
  6. Asberg M, Traskman L, Thoren P. 5-HIAA in the cerebrospinal fluid: A biochemical suicide predictor?. Arch. Gen. Psychiatry. 1976;33:1193–1197
  7. Beautrais AL, Joyce PR, Mulder RT, Ferguson DM, Deavoll BJ, Nightingale SK. Prevalence and co morbidity of mental disorders in persons making serious suicide attempts: a case control study. Am. J. Psychiatry. 1996;153:1009–1014
  8. Beck AT, Beck A, Kovacs M. Classification of suicidal behaviors I. Quantifying intent and medical lethality. Am. J. Psychiatry. 1975;132:285–287
  9. Brent DA, Bridge J, Johnson BA, Connolly J. Suicidal behavior runs in families. Arch. Gen. Psychiatry. 1996;53:1145–1152
  10. Brown GL, Goodwin FK, Ballenger PF, Goyer PF, Major LF. Aggression in humans correlates with cerebrospinal fluid amine metabolism. Psychiatry Res. 1979;1:131–139
  11. Brown GL, Ebert MH, Goyer PF, Jimerson DC, Klein NJ, Bunney WE, et al. Aggression, suicide, and serotonin: relationships to CSF amine metabolites. Am. J. Psychiatry. 1982;139:741–746
  12. Caldwell CB, Gottesman II. Schizophrenia — a high-risk factor for suicide: clues to risk reduction. Suicide and Life Threat. Behav. 1992;22:479–493
  13. Cleare AJ, Murray RM, O'Keane V. Reduced prolactin and cortisol responses to d-fenfluramine in depressed compared to healthy matched control subjects. Neuropsychopharmacology. 1996;14:349–354
  14. Coccaro EF, Kavoussi RJ, Hauger R. PRL and HVA responses to d- and d,l-fenfluramine in humans. Biol. Psychiatry. 1994;35:64
  15. Coccaro EF, Siever LJ, Klar HM, Maurer G, Cochrane K, Cooper TB, et al. Serotonergic studies in patients with affective and personality disorders. Correlates with suicidal and impulsive aggressive behavior. Arch. Gen. Psychiatry. 1989;46:587–599
  16. Cooper SJ, Kelly CB, King DJ. 5-Hydroxyindoleacetic acid in cerebrospinal fluid and prediction of suicidal behavior in schizophrenia. Lancet. 1992;340:940–941
  17. Correa H, Duval F, Mockani MC, Bailey P, Tremeau F, Staner L, et al. Prolactin response to d-fenfluramine and suicidal behavior in depressed patients. Psychiatry Res. 2000;93:189–199
  18. Diekstra RFW. The epidemiology of suicide and para suicide. Acta Psychiatr. Scand. 1993;371:6–20
  19. Diekstra RFW. Epidemiologie du suicide. L'Encephale Sp. 1996;IV:15–18
  20. Dorpat T, Ripley H. A study of suicide in the Seattle area. Comp. Psychiatry. 1960;1:349–359
  21. Duval F, Cambon N, Mokrani MC, Crocq MA, Bailey P, Diep TS, et al. Endocrine responses to dl- and d-fenfluramine in psychiatry. Biol. Psychiatry. 1994;35:646
  22. Duval F, Mokrani MC, Corrêa H, Crocq MA, Bailey P, Diep TS, et al. Hormonal responses to Dextro-fenfluramine in major depressive episode. Biol. Psychiatry. 1997;41:61
  23. Garattini S, Mennini T, Samanin R. From fenfluramine racemate to d-fenfluramine. Ann. N. Y. Acad. Sci. 1987;499:156–166
  24. Goldstein RB, Black DW, Nasrallah A, Winokur G. The prediction of suicide. Sensitivity, specificity, and predictive value of a multivariate model applied to suicide among 1906 patients with affective disorders. Arch. Gen. Psychiatry. 1991;48:418–422
  25. Goodal EM, Cowen J, Franklin M, Silverstone T. Ritanserin attenuates anorectic, endocrine and thermic responses to d-fenfluramine in human volunteers. Psychopharmacoloy. 1993;112:461–466
  26. Goodwin GM, Murray CL, Bancroft J. Oral d-fenfluramine and neuroendocrine challenge: problems with a the 30mg dose in men. J. Affect. Disord. 1994;30:117–122
  27. Gudelsky GA, Simonovic M, Meltzer HY. Dopaminergic and serotonergic control of neuroendocrine function. Monographs Neural Sci. 1984;10:85–102
  28. Hagnell O, Lanke J, Rorsman B. Suicide rates in the Lundbly study: mental illness as a risk factor for suicide. Neuropsychobiology. 1981;7:248–253
  29. Hamilton M. A rating scale for depression. J Neurol. Neurosurg. Psychiatr. 1960;23:56–62
  30. Harkavy-Friedman JM, Nelson EA. Assessement and intervention for the suicidal patient with schizophrenia. Psychiat. Q. 1997;68:361–375
  31. Higley JD, Thompson WW, Champoux M, Goldman D, Hasert MF, Kraemer GW, et al. Paternal and maternal genetic and environmental contributions to cerebrospinal fluid monoamone metabolites in rhesus monkeys (Macaca mulata). Arch. Gen. Psychiat. 1993;50:615–623
  32. Hogarty GE, McEvoy JP, Ulrich RF, DiBarry AL, Bartone P, Cooley S, et al. Pharmacology of impaired affect in recovering schizophrenic patients. Arch. Gen. Psychiat. 1995;52:29–41
  33. Invernizzi R, Berettera C, Garratini S, Samanin R. d- and l-isomers of fenfluramine differ markedly in their interaction with brain serotonin and catecholamines in the rat. Eur. J. Pharmacol. 1986;120:9–15
  34. Johns CA, Stanley M, Stanley B. Suicide in schizophrenia. Ann. N. Y. Acad. Sci. 1986;487:294–300
  35. Kasper S, Vieira A, Schmidt R, Richter P. Multiple hormone responses to stimulation with dl-fenfluramine in patients with major depression before and after antidepressive treatment. Pharmacopsychiat. 1990;23:76–84
  36. Kavoussi RJ, Kramer J, Hauger RL, Coccaro EF. Prolactin response to d-fenfluramine in outpatients with major depression. Psychiat. Res. 1998;79:199–205
  37. Leibenluft E, Fiero PL, Rubinow DR. Effects of the menstrual cycle on dependent variables in mood disorder research. Arch. Gen. Psychiat. 1994;51:761–781
  38. Leon AC, Friedman RA, Sweeney JA, Brown RP, Mann JJ. Statistical issues in the identification of risk factors for suicidal behavior: the application of survival analysis. Psychiat. Res. 1990;31:99–108
  39. Linkowski P, de Maertelaer V, Mendlewicz J. Suicidal behaviour in major depressive illness. Acta Psychiatr. Scand. 1985;72:233–238
  40. Lopez-Ibor JJ, Saiz-Ruiz J, Perez de los Cobos . Biological correlations of suicide and aggressivity in major depressions (with melancholia): 5-hydroxyindoleacetic acid and cortisol in cerebral spinal fluid, dexamethasone suppression test and therapeutic response to 5-hydroytryptophan. Neuropsychobiology. 1985;14:67–74
  41. Lopez-Ibor JJ, Saitz-Ruiz M, Iglesias M. The fenfluramine challenge test in the affective spectrum: a possible marker of endogenicity and severity. Pharmacopsychiatry. 1988;21:9–14
  42. Maes M, d'Hondt P, Suy E, Minner B, Vandervorst C, Raus J. HPA-axis hormones and prolactin responses to dextro-fenfluramine in depressed patients and healthy controls. Prog. Neuro-Psychopharmacol. Biol. Psychiat. 1991;15:781–790
  43. Malone KM, Corbitt EM, Shuhua L, Mann JJ. Prolactin response to fenfluramine and suicide lethality in major depression. Br. J. Psychiat. 1996;168:324–329
  44. Mann JJ, Arango P, Marzuk PM, Theccanat S, Reis DJ. Evidence for the 5-HT hypothesis of suicide. A review of post-mortem studies. Br. J. Psychiat. 1989;155:7–14
  45. Mann JJ, Malone KM, Diehl DJ, Perel J, Cooper TB, Mintun MA. Demonstration in vivo of reduced serotonin responsivity in the brain of untreated depressed patients. Am. J. Psychiat. 1996;153:174–182
  46. Mann JJ, Malone KM. Cerebrospinal fluid amines and higher-lethality suicide attempts in depressed inpatients. Biol. Psychiat. 1997;41:162–171
  47. Mann JJ, Malone KM, Nielsen DA, Goldman D, Erdos J, Gelernter J. Possible association of a polymorphism of the tryptophan hydroxylase gene with suicidal behavior in depressed patients. Am. J. Psychiat. 1997;154:1451–1453
  48. Mann JJ, Mc Bride PA, Brown RP, Linnoila M, Leon AC, De Meo M, et al. Relationship between central and peripheral serotonin indexes in depressed and suicidal psychiatric inpatients. Arch. Gen. Psychiat. 1992;49:442–446
  49. Mann JJ, Stanley M, McBride A, Mc Evans BS. Increased serotonin and adrenergic receptor binding in the frontal cortices of suicide victims (1986). Arch. Gen. Psychiat. 1986;43:954–959
  50. Meyer JH, Kennedy S, Brown GM. No effect of depression on [15O]H2O PET response to intravenous d-fenfluramine. Am. J. Psychiat. 1998;155:1241–1246
  51. Mohr P, Horacek J, Motlova L, Libiger J, Czobor P. Prolactin response to d-fenfluramine challenge test as a predictor of treatment response to haloperidol in acute schizophrenia. Schizophr. Res. 1998;30:91–99
  52. Mohr P, Horacek J, Motlova L, Libiger J, Czobor P. Effects of haloperidol treatment on prolactin response to d-fenfluramine challenge in acute schizophrenia. Psychopharmacology. 1999;141:322–325
  53. Mokrani MC, Duval F, Crocq MA, Bailey PE, Macher JP. Multihormonal responses to apomorphine in mental illness. Psychoneuroendocrinology. 1995;20:365–375
  54. Monteleone P, Tortorella A, Borriello R, Cassandro P, Maj M. Prolactin hyperresponsiveness to d-fenfluramine in drug-free schizophrenic patients: a placebo-controlled study. Biol. Psychiat. 1999;45:1606–1611
  55. Montgomery SA, Montgomery DB. Pharmacological prevention of suicidal behavior. J. Affect. Disord. 1982;4:291–298
  56. Nielsen DA, Goldman D, Virkkunen M, Tokola R, Rawlings R, Linnoila M. Suicidality and 5-hydroxyindoleacetic acid concentration associated with a tryptophan hydroxylase polymorphism. Arch. Gen. Psychiat. 1994;51:34–38
  57. Nielsen DA, Virkkunen M, Lappalainen J, Eggert M, Brown GL, Long JC, et al. A tryptophan hydroxylase gene marker for suicidality and alcoholism. Arch. Gen. Psychiat. 1998;55:593–602
  58. Ninan PT, van Kammen DP, Scheinin M, Linnoila M, Bunney WE, Goodwin FK. CSF 5-hydroxyindoleacetic acid levels in suicidal schizophenic patients. Am. J. Psychiat. 1984;141:566–569
  59. Nordstrom P, Samuelsson M, Asberg M, Traskman-Bendz L, Aberg-Wistedt A, Nordin C, et al. CSF 5-HIAA predicts suicide risk after attempt suicide. Suicide Life Threatening Behav. 1994;24:1–9
  60. O'keane V, Dinan TG. Prolactin and cortisol responses to d-fenfluramine in major depression: evidence for diminished responsivity of central serotonergic function. Am. J. Psychiat. 1991;14:1009–1015
  61. Overall JE, Gorman DR. The brief psychiatric rating scale. Psychol. Rep. 1962;10:799–812
  62. Palazidou E, Stephenson T, Butler J, Coskeran P, Chambers S, McGregor A. Evidence for 5-HT1A receptor involvement in the control of prolactin secretion in man. Psychopharmacoloy. 1995;119:311–314
  63. Park SB, Wlliamson DJ, Cowen PJ. 5-HT neuroendocrine function in major depression: prolactin and cortisol responses to d-fenfluramine. Psychol. Med. 1996;26:1191–1196
  64. Pfeffer CR, Normandin L, Kakuma T. Suicidal children grow-up: suicidal behavior and psychiatric disorders among relatives. J. Am. Acad. Chlid. Adolescent Psychiat. 1994;33:1087–1089
  65. Porkony AD. Prediction of suicide in psychiatric patients: a report of a prospective study. Arch. Gen. Psychiat. 1983;40:249–257
  66. Radomsky E, Haas GL, Mann JJ, Sweeney JA. Suicidal behavior in patients with schizophrenia and other psychotic disorders. Am. J. Psychiat. 1999;156:1590–1595
  67. Roy A. Risk factors for suicide in psychiatric patients. Arch. Gen. Psychiat. 1982;39:1089–1095
  68. Roy A. Family history of suicide. Arch. Gen. Psychiat. 1983;40:971–974
  69. Roy A, De Jong J, Linnoila M. Cerebrospinal fluid monoamine metabolites and suicidal behavior in depressed patients. A 5-year follow up study. Arch. Gen. Psychiat. 1989;46:609–612
  70. Roy A, Rylander G, Sarchiapone M. Genetics of suicide: family and molecular genetics. Ann. N.Y. Acad. Sci. 1997;836:135–157
  71. Roy A, Schreider J, Mazonson A, Pickar D. Suicidal behavior in chronic schizophrenic patients: a follow-up study. Can. J. Psychiat. 1986;31:737–740
  72. Siever LJ, Buchsbaum MS, New AS, Spiegel-Cohen J, Wei T, Hazlett EA, et al. d,l-Fenfluramine response in impulsive personality disorder assessed with [18F] fluorodeoxyglucose positron emission tomography. Neuropsychopharmacology. 1999;20(5):413–423
  73. Sisook S, McAdams LN, Kuck J, Harris MJ, Bailey A, Patterson TL, et al. Depressive symptoms in schizophrenia. Am. J. Psychiatry. 1999;156:1736–1743
  74. Spitzer RL, Endicott J. Schedule for Affective Disorders and Schizophrenia, Lifetime Version. New York, NY: Biometrics Research Division, New York State Psychiatric Institute; 1975;
  75. Van Prag HM. Depression, suicide and the metabolism of serotonin in the brain. J. Affect. Disord. 1982;4:275–290
  76. Van Praag HM. CSF 5-HIAA and suicide in non-depressed schizophrenics. Lancet. 1983;2:977–978

PII: S0920-9964(01)00181-5

doi: 10.1016/S0920-9964(01)00181-5

Schizophrenia Research
Volume 56, Issue 1 , Pages 75-85 , 1 July 2002

Article Tools

* Image Usage & Resolution